Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.172 SEK | +1.18% | +1.78% | -29.94% |
23/02 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
Business Summary
Number of employees: 8
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Mitochondrial Diseases
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 03/21/03 |
Eskil Elmér
FOU | Founder | 54 | 01/00/01 |
Director of Finance/CFO | 57 | 01/13/01 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | - | 01/23/01 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/08/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 28/16/28 | |
David Bejker
BRD | Director/Board Member | 49 | 27/17/27 |
Eskil Elmér
FOU | Founder | 54 | 01/00/01 |
Roger Franklin
BRD | Director/Board Member | 45 | 20/20/20 |
Denise Goode
BRD | Director/Board Member | 66 | 27/18/27 |
Director/Board Member | 64 | 27/17/27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,056,299,165 | 930,212,762 ( 88.06 %) | 0 | 88.06 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.94% | 20.99M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+2.56% | 22.18B | |
-16.67% | 21.2B | |
-9.05% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ABLI Stock
- Company Abliva AB